319 related articles for article (PubMed ID: 27075264)
1. Management of refractory typical GERD symptoms.
Scarpellini E; Ang D; Pauwels A; De Santis A; Vanuytsel T; Tack J
Nat Rev Gastroenterol Hepatol; 2016 May; 13(5):281-94. PubMed ID: 27075264
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.
Kung YM; Hsu WH; Wu MC; Wang JW; Liu CJ; Su YC; Kuo CH; Kuo FC; Wu DC; Wang YK
Dig Dis Sci; 2017 Dec; 62(12):3298-3316. PubMed ID: 29110162
[TBL] [Abstract][Full Text] [Related]
3. Refractory Gastroesophageal Reflux Disease: A Management Update.
Rettura F; Bronzini F; Campigotto M; Lambiase C; Pancetti A; Berti G; Marchi S; de Bortoli N; Zerbib F; Savarino E; Bellini M
Front Med (Lausanne); 2021; 8():765061. PubMed ID: 34790683
[TBL] [Abstract][Full Text] [Related]
4. Optimal management of severe symptomatic gastroesophageal reflux disease.
Talley NJ; Zand Irani M
J Intern Med; 2021 Feb; 289(2):162-178. PubMed ID: 32691466
[TBL] [Abstract][Full Text] [Related]
5. [Therapy of gastroesophageal reflux disease (GERD)].
Storr M
Med Monatsschr Pharm; 2011 Dec; 34(12):446-54; quiz 455-6. PubMed ID: 22233024
[TBL] [Abstract][Full Text] [Related]
6. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.
Iwakiri K; Kinoshita Y; Habu Y; Oshima T; Manabe N; Fujiwara Y; Nagahara A; Kawamura O; Iwakiri R; Ozawa S; Ashida K; Ohara S; Kashiwagi H; Adachi K; Higuchi K; Miwa H; Fujimoto K; Kusano M; Hoshihara Y; Kawano T; Haruma K; Hongo M; Sugano K; Watanabe M; Shimosegawa T
J Gastroenterol; 2016 Aug; 51(8):751-67. PubMed ID: 27325300
[TBL] [Abstract][Full Text] [Related]
7. Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease.
Watson TJ; Peters JH
Thorac Surg Clin; 2005 Aug; 15(3):405-15. PubMed ID: 16104131
[TBL] [Abstract][Full Text] [Related]
8. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial.
Boeckxstaens GE; Beaumont H; Hatlebakk JG; Silberg DG; Björck K; Karlsson M; Denison H
Gut; 2011 Sep; 60(9):1182-8. PubMed ID: 21402616
[TBL] [Abstract][Full Text] [Related]
9. Translational gastrointestinal pharmacology in the 21st century: 'the lesogaberan story'.
Boeckxstaens GE; Denison H; Jensen JM; Lehmann A; Ruth M
Curr Opin Pharmacol; 2011 Dec; 11(6):630-3. PubMed ID: 22036168
[TBL] [Abstract][Full Text] [Related]
10. Management of gastro-oesophageal reflux disease symptoms that do not respond to proton pump inhibitors.
Woodland P; Sifrim D
Curr Opin Gastroenterol; 2013 Jul; 29(4):431-6. PubMed ID: 23549342
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of laparoscopic fundoplication in relieving the symptoms of gastroesophageal reflux disease (GERD) and eliminating antireflux medical therapy.
Papasavas PK; Keenan RJ; Yeaney WW; Caushaj PF; Gagné DJ; Landreneau RJ
Surg Endosc; 2003 Aug; 17(8):1200-5. PubMed ID: 12739117
[TBL] [Abstract][Full Text] [Related]
13. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
[TBL] [Abstract][Full Text] [Related]
14. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.
Stefanidis G; Viazis N; Kotsikoros N; Tsoukalas N; Lala E; Theocharis L; Fassaris A; Manolakopoulos S
Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27868281
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapies for GERD.
van der Pol R; Benninga MA; Smout AJ
J Pediatr Gastroenterol Nutr; 2011 Dec; 53 Suppl 2():S10-1. PubMed ID: 22235450
[No Abstract] [Full Text] [Related]
16. Pathophysiology and pharmacological treatment of gastroesophageal reflux disease.
Storr M; Meining A; Allescher HD
Dig Dis; 2000; 18(2):93-102. PubMed ID: 11060472
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis and therapy of weakly-acid/non-acidic gastroesophageal reflux disease].
Meining A; Bajbouj M; Stein HJ; Schmid RM
Dtsch Med Wochenschr; 2005 Oct; 130(40):2266-9. PubMed ID: 16208602
[TBL] [Abstract][Full Text] [Related]
18. New algorithm for the treatment of gastro-oesophageal reflux disease.
Tytgat GN; McColl K; Tack J; Holtmann G; Hunt RH; Malfertheiner P; Hungin AP; Batchelor HK
Aliment Pharmacol Ther; 2008 Feb; 27(3):249-56. PubMed ID: 17973975
[TBL] [Abstract][Full Text] [Related]
19. Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.
Vakil NB; Huff FJ; Cundy KC
Aliment Pharmacol Ther; 2013 Jul; 38(2):107-17. PubMed ID: 23721547
[TBL] [Abstract][Full Text] [Related]
20. The effect of endoscopic fundoplication and proton pump inhibitors on baseline impedance and heartburn severity in GERD patients.
Rinsma NF; Farré R; Bouvy ND; Masclee AA; Conchillo JM
Neurogastroenterol Motil; 2015 Feb; 27(2):220-8. PubMed ID: 25348594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
